Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence
and Launch of Late-Stage Biologics will Drive the Market in Spite of
Affordability Concerns
Summary
Asthma is a common chronic inflammatory disease of the airways,
characterized by recurrent attacks of breathlessness and wheezing, which
vary in frequency and severity from patient to patient. The exact
causes of asthma are currently unknown, and may be the result of a
combination of factors, although two major factors thought to be
involved are environmental exposure and host factors, particularly
genes.
Browse Detail Report With TOC @
Asthma treatment can be classed as either a long-term control
medication, aimed at controlling persistent asthma, or a quick-relief
medication, for the relief of exacerbations and acute symptoms.
Long-term control medication includes Inhaled Corticosteroids (ICS),
immunomodulators, leukotriene modifiers, cromolyn sodium, nedocromil and
methylxanthines.
In addition, Long-Acting Beta-Adrenoceptor Agonists (LABAs) can be
used in combination with ICSs – but not as monotherapies
– for moderate or severe persistent asthma. Currently, only
one biologic – Xolair (omalizumab) – is approved as
an add-on therapy for the treatment of allergic asthma in the
Asia-Pacific region. Nevertheless, significant unmet need
remains for the treatment of severe eosinophilic asthma.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/105553
Scope
The current asthma market in the Asia-Pacific region contains novel
products, including Xolair, a recombinant humanized monoclonal anti-IgE
antibody; Seretide/Adoair, an ICS-LABA combination therapy; Relvar/Breo,
an ICS-LABA combination therapy, and Spiriva, a LAMA.
- What are the competitive advantages of the existing novel drugs?
- With over 274 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, with improved dosing regimens and administration routes in comparison to currently marketed products.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the asthma market – specifically for severe eosinophilic asthma?
- Analysis of clinical trials since 2006 has identified that the failure rates of asthma molecules were highest in Phase III (46%), with the overall attrition rate for asthma in development being 78%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
- Over the 2014–2021 forecast period, the asthma therapeutics market in the Asia-Pacific region is expected to increase in value at a Compound Annual Growth Rate (CAGR) of 7.2%, from $3.5 billion to over $5.6 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
- Rising asthma prevalence and uptake of newer biologics will lead to significant market growth over the forecast period, in spite of affordability concerns.
- Will affordability threaten the commercial success of existing drugs as well as newer biologics?
- Which of the assessed countries have affordability concerns?
Hexa Reports is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Website: http://www.hexareports.com/
Visit our Blog: http://hexareports.blogspot.com/
No comments:
Post a Comment